Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the effect of body changes in pregnancy on
doravirine concentrations, to determine what dose of doravirine should be used. Study
participants will remain on their normal antiretroviral medications (ARVs) while
participating in this study as prescribed by their regular clinic provider. Study
participants will come to the research clinic for three sampling visits throughout their time
as a participant. Study participants will only take one dose of doravirine during each
sampling visit, which will occur during the 2nd and 3rd trimesters, as well as after their
baby is delivered. This study was designed intentionally to not give a dose of doravirine in
the first trimester when there is the greatest chance for all drugs to potentially cause
injury to the baby. Study participants that choose to participate in this study may be
enrolled for up to 10 months depending on the length of their pregnancy and how the visits
are scheduled.